Dihydronicotinamide Mononucleotide Disodium Salt

Dihydronicotinamide mononucleotide disodium salt (NMN) is a reduced form of nicotinamide mononucleotide, a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme critical for cellular energy metabolism, DNA repair, and sirtuin activation. While preclinical studies suggest that NMN supplementation may enhance NAD+ levels and improve metabolic and age-related physiological decline, clinical evidence in humans remains limited and inconsistent. Recent meta-analyses of randomized controlled trials show that NMN supplementation (250–2000 mg/day for up to 12 weeks) significantly increases blood NAD+ levels, but does not consistently improve markers of glucose metabolism (e.g., fasting glucose, insulin, HbA1c) or lipid profiles in middle-aged and older adults [1]. Notably, one preclinical study in mice found that NMN supplementation blunted the beneficial effects of exercise on glucose metabolism in diet-induced obesity, raising concerns about context-specific efficacy [2]. Overall, while NMN effectively raises NAD+ in humans, its functional health benefits remain unproven, and long-term safety and optimal dosing are not well established [3][4].